Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression
Elia E. Acevedo-Diaz, Grace W. Cavanaugh, Dede Greenstein, et al.
Journal of Affective Disorders (2019) Vol. 263, pp. 568-575
Open Access | Times Cited: 81

Showing 1-25 of 81 citing articles:

The role of dissociation in ketamine’s antidepressant effects
Elizabeth D. Ballard, Carlos A. Zarate
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 140
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Ioline D. Henter, Lawrence T. Park, Carlos A. Zarate
CNS Drugs (2021) Vol. 35, Iss. 5, pp. 527-543
Open Access | Times Cited: 108
The antidepressant actions of ketamine and its enantiomers
Jenessa N. Johnston, Ioline D. Henter, Carlos A. Zarate
Pharmacology & Therapeutics (2023) Vol. 246, pp. 108431-108431
Open Access | Times Cited: 72
Ketamine in neuropsychiatric disorders: an update
Jenessa N. Johnston, Bashkim Kadriu, Christoph Kraus, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 23-40
Closed Access | Times Cited: 47
The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence
Roger S. McIntyre, Nelson B. Rodrigues, Yena Lee, et al.
Journal of Affective Disorders (2020) Vol. 274, pp. 903-910
Closed Access | Times Cited: 96
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Bashkim Kadriu, Maximillian Greenwald, Ioline D. Henter, et al.
The International Journal of Neuropsychopharmacology (2020) Vol. 24, Iss. 1, pp. 8-21
Open Access | Times Cited: 81
A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics
Neil K. Savalia, Ling-Xiao Shao, Alex C. Kwan
Trends in Neurosciences (2020) Vol. 44, Iss. 4, pp. 260-275
Open Access | Times Cited: 81
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur
Jennifer Swainson, Alexander McGirr, Pierre Blier, et al.
The Canadian Journal of Psychiatry (2020) Vol. 66, Iss. 2, pp. 113-125
Open Access | Times Cited: 78
Ketamine for depression
Luke A. Jelen, James Stone
International Review of Psychiatry (2021) Vol. 33, Iss. 3, pp. 207-228
Closed Access | Times Cited: 70
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders
Felicia Ceban, Joshua D. Rosenblat, Kevin Kratiuk, et al.
CNS Drugs (2021) Vol. 35, Iss. 9, pp. 925-934
Closed Access | Times Cited: 61
Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression
Fraser Scott, Elliot Hampsey, Sam Gnanapragasam, et al.
Journal of Psychopharmacology (2022) Vol. 37, Iss. 3, pp. 268-278
Open Access | Times Cited: 47
The abuse liability of ketamine: A scoping review of preclinical and clinical studies
Tuyen T. Le, Isabel Pazos Cordero, Muhammad Youshay Jawad, et al.
Journal of Psychiatric Research (2022) Vol. 151, pp. 476-496
Closed Access | Times Cited: 43
Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression
Guang Chen, Li Chen, Yun Zhang, et al.
The International Journal of Neuropsychopharmacology (2022) Vol. 25, Iss. 4, pp. 269-279
Open Access | Times Cited: 42
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
Fabrice Jollant, Romain Colle, Thi Mai Loan Nguyen, et al.
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 33
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research
Hartej Gill, Barjot Gill, Nelson B. Rodrigues, et al.
Neuroscience & Biobehavioral Reviews (2020) Vol. 120, pp. 78-85
Closed Access | Times Cited: 66
Remission from Chronic Anorexia Nervosa With Ketogenic Diet and Ketamine: Case Report
Barbara Scolnick, Beth Zupec‐Kania, Lori Calabrese, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 51
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence
Nelson B. Rodrigues, Roger S. McIntyre, Orly Lipsitz, et al.
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 8, pp. 1031-1040
Closed Access | Times Cited: 40
Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
Naghmeh Nikkheslat
Brain Behavior & Immunity - Health (2021) Vol. 18, pp. 100383-100383
Open Access | Times Cited: 38
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing
Jennifer Swainson, Larry J. Klassen, Stefan Brennan, et al.
CNS Drugs (2022) Vol. 36, Iss. 3, pp. 239-251
Open Access | Times Cited: 24
Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis
Itsuki Terao, Takahiro Tsuge, Kaori Endo, et al.
Journal of Affective Disorders (2023) Vol. 346, pp. 49-56
Closed Access | Times Cited: 14
Neurophysiological correlates of ketamine-induced dissociative state in bipolar disorder: insights from real-world clinical settings
Claudio Agnorelli, Alessandra Cinti, G. Barillà, et al.
Molecular Psychiatry (2025)
Open Access
Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Alejandra Pulido-Saavedra, Henrique Nunes Pereira Oliva, Tiago Paiva Prudente, et al.
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
Ketamine effects on resting state functional brain connectivity in major depressive disorder patients: a hypothesis-driven analysis based on a network model of depression
Kasper Recourt, Joop van Gerven, Nadieh Drenth, et al.
Frontiers in Neuroscience (2025) Vol. 19
Open Access
Single and repeated ketamine treatment induces perfusion changes in sensory and limbic networks in major depressive disorder
Ashish Sahib, Joana Loureiro, Megha Vasavada, et al.
European Neuropsychopharmacology (2020) Vol. 33, pp. 89-100
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top